ANTICONVULSANT DRUGS MARKET ANALYSIS

Anticonvulsant Drugs Market, by Drug Class (Barbiturates, Benzodiazepines, Aromatic allylic alcohols, Carboxamides, Triazine, AMPA receptor antagonists, Carbamate, Hydantoin, Fatty Acid Derivative, GABA analogs, Valproylamides, Others (Propionates, Oxazolidinediones, etc.)), by Route of Administration (Enteral, Parenteral), by Indication (Epilepsy, Neuropathic pain, Anxiety, Fibromyalgia, Bipolar Disorder, Others (Borderline personality disorder, etc.)), by Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Jan 2023
Code : CMI2516
Pages :170
Formats :
Excel and PDF
Industry : Pharmaceutical

Market News

Global Anticonvulsant Drugs Market: Key Developments

In June 2022, the Government of Manitoba, a Canadian province, announced an annual investment of more than US$ 2.5 million in operating funding to support the establishment of the adult epilepsy surgery program, as well as the expansion of the pediatric program, which has completed about 15 surgeries per year since 2017. When the expanded program will be fully operational, around 50 epilepsy surgeries will be completed per year in Manitoba including 20 adult and 30 pediatric cases. The program, including surgeries, will be run at Health Sciences Centre (HSC) Winnipeg, a hospital in Manitoba.

Global Anticonvulsant Drugs Market: Restraint

Increasing number of product recall by regulatory authorities such U.S. Food and Drug Administration is expected to hamper the growth of anticonvulsant drugs market. For instance, in January 2022, U.S. Food and Drug Administration recalled 15,336 bottles of 200-mg carbamazepine tablets, which was manufactured by Torrent Pharmaceuticals Ltd., a pharmaceutical company. The product was recalled because samples failed to meet dissolution specifications during testing.